EJNMMI Radiopharmacy and Chemistry
Aims and scope
EJNMMI Radiopharmacy and Chemistry publishes new research in the field of development of new imaging and radionuclide-based therapeutic agents for application in nuclear medicine and molecular imaging. The journal provides a platform for chemists, pharmacists, biologists and basic scientists to present their views and scientific work. In addition, the journal provides insight into novel concepts of imaging or radionuclide-based therapeutic agent applications of relevance for the whole molecular imaging community.
The journal reports original research articles, review papers, guidelines on the application of imaging or radionuclide therapy agents, editorials, and letters to the editor. Research articles on novel production methods of radionuclides, novel radiochemistry, new radiopharmaceuticals including their first biological evaluation, molecular imaging agents including optical imaging, MRI, and hybrid probes, are the main focus of the journal. To foster daily practice in the community the journal stimulates submission regarding best practice and harmonization of methodologies. To translate imaging and radionuclide therapy agents to the clinic, legislative issues related to their production and safety can be presented as well in the form of guidelines or position papers.
To further serve the community the journal publishes abstracts of radiopharmaceutical-oriented congresses.
Open calls for papers
Articles
-
Development of an automated method for in-house production of sodium 18F-fluoride for injection: process validation as a step toward routine clinical application
Authors: Marija Atanasova Lazareva, Maja Chochevska, Katerina Kolevska, Maja Velickovska, Filip Jolevski, Paulina Apostolova, Ana Ugrinska and Emilija Janevik-Ivanovska
Content type: Research article 4 February 2025
-
Synthesis and in vitro evaluation of spirobenzovesamicols as potential 11C-PET tracer alternatives to [18F]FEOBV for vesicular acetylcholine transporter (VAChT) imaging
Authors: Hugo Helbert, Winnie Deuther-Conrad, Michel de Haan, Barbara Wenzel, Gert Luurtsema, Wiktor Szymanski, Peter Brust, Rudi A. J. O. Dierckx, Ben L. Feringa and Philip H. Elsinga
Content type: Research article 2 February 2025
-
The N-acetyltransferase 10 inhibitor [11C]remodelin: synthesis and preliminary positron emission tomography study in mice
Authors: Rui Luo, Yiding Zhang, Katsushi Kumata, Lin Xie, Yusuke Kurihara, Masanao Ogawa, Tomomi Kokufuta, Nobuki Nengaki, Feng Wang and Ming-Rong R. Zhang
Content type: Research article 31 January 2025
-
Lutetium-177 labeled iPD-L1 as a novel immunomodulator for cancer-targeted radiotherapy
Authors: Myrna Luna-Gutiérrez, Erika Azorín-Vega, Rigoberto Oros-Pantoja, Blanca Ocampo-García, Pedro Cruz-Nova, Nallely Jiménez-Mancilla, Gerardo Bravo-Villegas, Clara Santos-Cuevas, Laura Meléndez-Alafort and Guillermina Ferro-Flores
Content type: Research article 22 January 2025
-
Rapid fabrication and dissolution of pressed 58Ni/Mg matrix targets for 55Co production
Authors: Jonathan Siikanen, Stefan Milton, Klas Bratteby, Wilson Lin, Jonathan W. Engle, Emma Jussing and Thuy A. Tran
Content type: Research article 21 January 2025
-
Auger electrons for cancer therapy – a review
Content type: Review 11 October 2019
-
Guideline on current good radiopharmacy practice (cGRPP) for the small-scale preparation of radiopharmaceuticals
Authors: Nic Gillings, Olaug Hjelstuen, Jim Ballinger, Martin Behe, Clemens Decristoforo, Philip Elsinga, Valentina Ferrari, Petra Kolenc Peitl, Jacek Koziorowski, Peter Laverman, Thomas L. Mindt, Oliver Neels, Meltem Ocak, Marianne Patt and Sergio Todde
Content type: Guideline article 12 February 2021
-
Guidance on validation and qualification of processes and operations involving radiopharmaceuticals
Authors: S. Todde, P. Kolenc Peitl, P. Elsinga, J. Koziorowski, V. Ferrari, E. M. Ocak, O. Hjelstuen, M. Patt, T. L. Mindt and M. Behe
Content type: Guideline article 29 June 2017
-
EANM guideline on the validation of analytical methods for radiopharmaceuticals
Authors: Nic Gillings, Sergio Todde, Martin Behe, Clemens Decristoforo, Philip Elsinga, Valentina Ferrari, Olaug Hjelstuen, Petra Kolenc Peitl, Jacek Koziorowski, Peter Laverman, Thomas L. Mindt, Meltem Ocak and Marianne Patt
Content type: Guideline article 12 February 2020
-
EANM guideline for harmonisation on molar activity or specific activity of radiopharmaceuticals: impact on safety and imaging quality
Authors: Gert Luurtsema, Verena Pichler, Salvatore Bongarzone, Yann Seimbille, Philip Elsinga, Antony Gee and Johnny Vercouillie
Content type: Guideline article 9 October 2021
Need help with APC funding?
We offer a free open access support service to make it easier for you to discover and apply for article-processing charge (APC) funding. Learn more here.
Check if your institution is a member
More than 500 institutions have partnered with BMC through the membership program. As an affiliated Author from a member institution, you may be entitled to submit your manuscript without paying the article processing charge (APC) or with a discount. Check here if your institution is a member!
EJNMMI Radiopharmacy and Chemistry - Kindly explore our collections here
Topical Collections about latest and interesting topics in EJNMMI Radiopharmacy and Chemistry are available at: https://ejnmmipharmchem.springeropen.com/articles/collections
The EJNMMI Journal Family and EANM Springer Award
Highlights of our featured content and the latest developments from the EJNMMI group of journals can be found on the EJNMMI Journal Family webpage. There you will also find details about the annual EANM Springer Prize.
Annual Journal Metrics
-
Citation Impact 2023
Journal Impact Factor: 4.4
5-year Journal Impact Factor: 4.7
Source Normalized Impact per Paper (SNIP): 1.356
SCImago Journal Rank (SJR): 0.869Speed 2024
Submission to first editorial decision (median days): 9
Submission to acceptance (median days): 61Usage 2024
Downloads: 341,572
Altmetric mentions: 72
Follow
- ISSN: 2365-421X (electronic)
Affiliated with